Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arbios bags $4.8m for Sepet trials:

This article was originally published in Clinica

Executive Summary

Waltham, Massachusetts-based biomedical device and cell therapy company Arbios is another step closer to taking its Sepet liver assist device to market, having pocketed $4.8m from a private placement of stocks and warrants. MicroCapital led the financing round. The proceeds will enable the company to go ahead with plans for CE-marking the Sepet, as well as initiating pivotal clinical trials of the device to support its application for US approval. Arbios' Sepet liver assist device, designed for use with standard blood dialysis systems, helps to purify the blood of patients with chronic liver failure caused by hepatitis B, hepatitis C or alcoholic cirrhosis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel